Biolinq, a San Diego, CA-based health technology company, expanded its Series A financing with an additional investment of $4.75m.
The round was led by the JDRF T1D Fund, Aphelion Capital and LifeSci Venture Partners, which joined a syndicate of existing investors, including M Ventures and Hikma Ventures, the corporate venture capital arm of Hikma Pharmaceuticals (LON:HIK).
The investment brings Biolinq’s total Series A funding to $15m.
The company intends to use the funds to grow its innovative technology platform and fund additional clinical studies.
Founded in 2012 (as Electrozyme, LLC) and led by Jared Tangney, CEO, Biolinq is a health technology company with a wirelessly-enabled biosensor patch capable of continuously monitoring multiple biomarkers. Its first commercial product, a unique minimally-invasive technology, will allow people living with diabetes to continuously monitor their blood glucose without the pain and hassle of traditional continuous glucose monitoring (CGM) systems.